Scripps Research Logo

News Release

Scripps Research Institute and OPKO Health Announce Global License Agreement for a Novel Compound That Blocks Brain Cell Destruction in Parkinson’s Disease

MIAMI, FL and JUPITER, FL, March 9, 2012 – The Scripps Research Institute and OPKO Health, Inc. (NYSE: OPK) today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson’s disease.

“This licensing agreement will help insure that the development of this promising compound keeps moving forward,” said Scripps Research Professor Philip LoGrasso, Ph.D., whose laboratory has led the research on the compound to date. “This is one of the best opportunities we have for the development of an effective neuroprotective treatment for Parkinson’s patients.”

Under the terms of the agreement, Scripps Research has granted to OPKO Health exclusive worldwide rights to develop, manufacture, and commercialize SR 3306 and related compounds that inhibit a class of enzymes called jun-N-terminal kinsases (JNK) that play an important role in neuron survival. The new compound would potentially be the first to protect the brain from the ravages of Parkinson's disease.

“We are excited to be working with Dr. LoGrasso and The Scripps Research Institute to develop this important compound which could prevent the progression of Parkinson’s disease and not just treat the symptoms of the disease,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.

Parkinson's disease, a degenerative neurological disorder that reduces the brain's ability to produce dopamine, affects about 1 million Americans. Currently prescribed drugs for Parkinson’s disease—including levodopa and so-called MAO-B inhibitors—can counteract symptoms of the disease but not stop its progression.

The LoGrasso lab described SR-3306 in a pair of studies published in February 2011 in the journal ACS Chemical Neuroscience.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see

About OPKO Health, Inc.

OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

Forward Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the anticipated benefits and opportunities of SR 3306, such as statements about its ability to prevent the progression of Parkinson’s disease, block the destruction of brain cells in patients with Parkinson’s disease and protect the brain from the ravages of the disease, as well as statements that SR 3306 represents one of the best opportunities we have for the development of an effective neuroprotective treatment for Parkinson’s patients. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in OPKO’s filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and neither OPKO or Scripps undertakes any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

# # #

For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8136